Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib demonstrated in vitro reduction of vascular inflammatory drivers underlying pulmonary hypertension

Friday, January 30, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Seralutinib has shown in vitro effectiveness in reducing the vascular inflammatory drivers associated with pulmonary hypertension. This finding suggests that the drug may play a crucial role in managing this condition. The results could lead to improved treatment options for patients suffering from pulmonary hypertension.
Price reaction · baseline $2.42 (2026-01-29 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close · peak
-5.8%
day 1
+2.5%
day 3
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows promise in reducing vascular inflammation.
  • Demonstrated efficacy in addressing pulmonary hypertension drivers.
  • Potential for significant impact on patient outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib demonstrated in vitro reduction of vascular inflammatory drivers underlying pulmonary hypertension
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib?

Seralutinib is a drug being studied for its effects on pulmonary hypertension.

How does Seralutinib work?

It reduces vascular inflammatory drivers associated with pulmonary hypertension.

What are the implications of this study?

The study suggests Seralutinib may improve treatment options for pulmonary hypertension.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary hypertension vascular inflammation in vitro
Last updated: Jan 30, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →